Targeting DNA repair mechanisms, tumor genetics, and signaling pathways: Synergistic approaches in gastrointestinal cancer treatment

Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books in Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR).

Bassel F. El-Rayes, M.D., is the deputy director of the UAB O’Neal Comprehensive Cancer Center, a senior scientist at the O’Neal Cancer Center, a professor of Medicine and the director of the Division of Hematology & Oncology in the UAB Department of Medicine. Dr. El-Rayes is focused translational research and drug development in gastrointestinal cancer with special emphasis on pancreatobiliary and neuroendocrine cancers. El-Rayes has served as principal investigator on several peer-reviewed NCI grants, investigator-initiated trials and multi-institutional trials. He has published more than 250 peer-reviewed scientific articles. He has served on several national committees, including the NCI Neuroendocrine Tumor Task Force and the National Committee of the American Society of Clinical Oncology for the development of guidelines for the management of central venous catheters in patients with cancer.